NASDAQ:ABIO ARCA biopharma (ABIO) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free ABIO Stock Alerts $3.26 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$3.25▼$3.4650-Day Range$1.63▼$3.6552-Week Range$1.56▼$3.88Volume16,945 shsAverage Volume1.06 million shsMarket Capitalization$47.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ARCA biopharma alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About ARCA biopharma Stock (NASDAQ:ABIO)ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Read More ABIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABIO Stock News HeadlinesMay 1, 2024 | msn.comNoah Gragson Expands 2024 Schedule with NASCAR Xfinity and ARCA RacesApril 30, 2024 | msn.comNoah Gragson adds NASCAR Xfinity, ARCA races to 2024 scheduleMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 28, 2024 | msn.comConnor Zilisch wins ARCA Menards Series race at Dover, first of his careerApril 28, 2024 | americanbankingnews.comARCA biopharma (NASDAQ:ABIO) Now Covered by StockNews.comApril 27, 2024 | msn.comConnor Zilisch reacts to winning first ARCA race as NASCAR career takes next stepApril 27, 2024 | msn.comRed Flags at Dover as Scary Head-On Crash Leaves Amber Balcaen Limping After Attempt to Avoid ARCA Star's Flaming FiascoApril 26, 2024 | americanbankingnews.comARCA biopharma, Inc. (NASDAQ:ABIO) Short Interest UpdateMay 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 25, 2024 | investorplace.comABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024April 25, 2024 | globenewswire.comARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate UpdateApril 20, 2024 | money.usnews.comARCA biopharma IncApril 20, 2024 | msn.com18-year-old Jake Finch leads every lap to capture ARCA victory at TalladegaApril 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIOApril 5, 2024 | businesswire.comARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIOApril 3, 2024 | investorplace.comWhy Is ARCA Biopharma (ABIO) Stock Up 85% Today?April 3, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with OrukaApril 3, 2024 | marketwatch.comARCA Biopharma in Reverse Merger Pact With Oruka TherapeuticsApril 3, 2024 | msn.comFibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare moversApril 3, 2024 | bizjournals.comNew Paragon spinout lands $275M financing — and reverse mergerApril 3, 2024 | markets.businessinsider.comARCA Biopharma, Oruka Therapeutics To Combine In All-stock Deal - Quick FactsApril 3, 2024 | msn.comSmall-Cap ARCA Biopharma Stock Soars On Merger Pact: The DetailsApril 3, 2024 | businesswire.comABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to ShareholdersApril 3, 2024 | globenewswire.comARCA biopharma and Oruka Therapeutics Announce Merger AgreementApril 3, 2024 | globenewswire.comARCA biopharma and Oruka Therapeutics Announce Merger AgreementMarch 27, 2024 | msn.comARCA Sensation Toni Breidinger Divulges Struggles of ‘Imposter’ Feeling in Male-Dominated NASCARMarch 19, 2024 | finance.yahoo.comRx Outreach builds first St. Louis community pharmacy in partnership with ARCA to rid barriers, promote healthSee More Headlines Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2021Today5/03/2024Next Earnings (Estimated)7/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:ABIO CUSIPN/A CIK907654 Webarcabio.com Phone(720) 940-2100Fax720-208-9261Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-16.08% Return on Assets-15.51% Debt Debt-to-Equity RatioN/A Current Ratio23.19 Quick Ratio23.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.42 per share Price / Book1.35Miscellaneous Outstanding Shares14,507,000Free Float10,024,000Market Cap$47.29 million OptionableOptionable Beta0.89 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Thomas A. Keuer (Age 65)President, COO & Principal Executive Officer Comp: $400.8kMr. C. Jeffrey Dekker CPA (Age 59)CFO, Treasurer & Company Secretary Comp: $323.07kKey CompetitorsAspira Women's HealthNASDAQ:AWHImmuCellNASDAQ:ICCCAlpha TeknovaNASDAQ:TKNOVolitionRxNYSE:VNRXOncoCyteNASDAQ:OCXView All CompetitorsInstitutional OwnershipCable Car Capital LLCBought 4,000,452 shares on 2/20/2024Ownership: 27.589%View All Institutional Transactions ABIO Stock Analysis - Frequently Asked Questions How have ABIO shares performed in 2024? ARCA biopharma's stock was trading at $1.70 at the beginning of 2024. Since then, ABIO stock has increased by 91.8% and is now trading at $3.26. View the best growth stocks for 2024 here. Are investors shorting ARCA biopharma? ARCA biopharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 5,660,000 shares, an increase of 2,792.2% from the March 31st total of 195,700 shares. Based on an average daily trading volume, of 1,380,000 shares, the days-to-cover ratio is currently 4.1 days. Currently, 39.6% of the shares of the stock are short sold. View ARCA biopharma's Short Interest. When is ARCA biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 19th 2024. View our ABIO earnings forecast. How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) announced its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($2.37) by $2.03. What is Michael R. Bristow's approval rating as ARCA biopharma's CEO? 1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP). Who are ARCA biopharma's major shareholders? ARCA biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher David Ozeroff, Fund Lp Funicular and Robert E Conway. View institutional ownership trends. How do I buy shares of ARCA biopharma? Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABIO) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
